Successful treatment with sorafenib in patients with advanced hepatocellular carcinoma: clinical case

Multi-kinase inhibitor sorafenib is the only one drug which increases life time in patients with advanced hepatocellular carcinoma (HCC). Results from the SHARP trial showed that median progression-free survival was less than 5 months. However, it is possible to achieve strong treatment effect for s...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu V Bisovskaya, V V Breder, B M Medvedeva, V A Gorbunova
Format: Artigo
Language:Russo
Published: IP Habib O.N. 2014-06-01
Series:Современная онкология
Subjects:
hepatocellular carcinoma
sorafenib
chronic hepatitis b
lamivudine
Online Access:https://modernonco.orscience.ru/1815-1434/article/view/26969
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items